Citation
Locher, Hans H., et al. "In Vitro and in Vivo Antibacterial Evaluation of Cadazolid, a New Antibiotic for Treatment of Clostridium Difficile Infections." Antimicrobial Agents and Chemotherapy, vol. 58, no. 2, 2014, pp. 892-900.
Locher HH, Seiler P, Chen X, et al. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob Agents Chemother. 2014;58(2):892-900.
Locher, H. H., Seiler, P., Chen, X., Schroeder, S., Pfaff, P., Enderlin, M., Klenk, A., Fournier, E., Hubschwerlen, C., Ritz, D., Kelly, C. P., & Keck, W. (2014). In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrobial Agents and Chemotherapy, 58(2), 892-900. https://doi.org/10.1128/AAC.01830-13
Locher HH, et al. In Vitro and in Vivo Antibacterial Evaluation of Cadazolid, a New Antibiotic for Treatment of Clostridium Difficile Infections. Antimicrob Agents Chemother. 2014;58(2):892-900. PubMed PMID: 24277020.
TY - JOUR
T1 - In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.
AU - Locher,Hans H,
AU - Seiler,Peter,
AU - Chen,Xinhua,
AU - Schroeder,Susanne,
AU - Pfaff,Philippe,
AU - Enderlin,Michel,
AU - Klenk,Axel,
AU - Fournier,Elvire,
AU - Hubschwerlen,Christian,
AU - Ritz,Daniel,
AU - Kelly,Ciaran P,
AU - Keck,Wolfgang,
Y1 - 2013/11/25/
PY - 2013/11/27/entrez
PY - 2013/11/28/pubmed
PY - 2014/9/23/medline
SP - 892
EP - 900
JF - Antimicrobial agents and chemotherapy
JO - Antimicrob Agents Chemother
VL - 58
IS - 2
N2 - Clostridium difficile is a leading cause of health care-associated diarrhea with significant morbidity and mortality, and new options for the treatment of C. difficile-associated diarrhea (CDAD) are needed. Cadazolid is a new oxazolidinone-type antibiotic that is currently in clinical development for treatment of CDAD. Here, we report the in vitro and in vivo antibacterial evaluation of cadazolid against C. difficile. Cadazolid showed potent in vitro activity against C. difficile with a MIC range of 0.125 to 0.5 μg/ml, including strains resistant to linezolid and fluoroquinolones. In time-kill kinetics experiments, cadazolid showed a bactericidal effect against C. difficile isolates, with >99.9% killing in 24 h, and was more bactericidal than vancomycin. In contrast to metronidazole and vancomycin, cadazolid strongly inhibited de novo toxin A and B formation in stationary-phase cultures of toxigenic C. difficile. Cadazolid also inhibited C. difficile spore formation substantially at growth-inhibitory concentrations. In the hamster and mouse models for CDAD, cadazolid was active, conferring full protection from diarrhea and death with a potency similar to that of vancomycin. These findings support further investigations of cadazolid for the treatment of CDAD.
SN - 1098-6596
UR - https://www.unboundmedicine.com/medline/citation/24277020/In_vitro_and_in_vivo_antibacterial_evaluation_of_cadazolid_a_new_antibiotic_for_treatment_of_Clostridium_difficile_infections_
L2 - http://aac.asm.org/cgi/pmidlookup?view=long&pmid=24277020
DB - PRIME
DP - Unbound Medicine
ER -